Skip to main content

Advertisement

SpringerLink
Log in

Evolving Screening and Vaccination Recommendations for Hepatitis B in the USA

  • Hepatitis B (J Lim, Section Editor)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Screening for hepatitis B viral infection in the USA is currently recommended for high-risk individuals and pregnant persons. Effective vaccines for hepatitis B have been available since the early 1980s, and have been recommended as part of the universal childhood immunization series since the 1990s.

Recent Findings

Vaccination rates remain low among the general population of persons who were not vaccinated in childhood or adolescence; despite efforts to increase adult vaccination rates, persons at highest risk of exposure—for example, injection drug users—may also be among those with low access to health care.

Summary

Although there is limited data to support universal screening for hepatitis B, newer vaccine regimens with fewer doses may address some challenges to improving rates of vaccination among US adults with and without risk factors for infection. The following review summarizes evolving recommendations for hepatitis B screening and vaccination in the USA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Viral hepatitis surveillance — United States. Centers for Disease Control and Prevention.

  2. Public health reporting and national notification for acute hepatitis B infections. Council of State and Territorial Epidemiologists;Position statement 11-ID-03.

  3. Roberts H, Ly KN, Yin S, Hughes E, Teshale E, Jiles R. Prevalence of hepatitis B virus (HBV) infection, vaccine-induced immunity, and susceptibility among at-risk populations: U.S. households, 2013-2018. Hepatology 2021.

  4. Wong RJ, Brosgart CL, Welch S, Block T, Chen M, Cohen C, Kim WR, et al. An updated assessment of chronic hepatitis B prevalence among foreign-born persons living in the United States. Hepatology. 2021.

  5. Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Donahue K, et al. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. Jama. 2020;324:2415–22.

    Article  Google Scholar 

  6. Tang LSYCE, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319:1802–13.

    Article  CAS  Google Scholar 

  7. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.

    Article  Google Scholar 

  8. David H. Spach M, Maria A. Corcorran, MD. HBV screening and diagnosis. Hepatitis B Online 2021.

  9. Wong RJ, Brosgart CL, Welch S, Block T, Chen M, Cohen C, Kim WR, et al. An updated assessment of chronic hepatitis B prevalence among foreign-born persons living in the United States. Hepatology. 2021;74:607–26.

    Article  Google Scholar 

  10. Wolffram IPD, Bätz O, et al. German Check-Up 35+ Study Group. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol. 2015;62:1256–64.

    Article  CAS  Google Scholar 

  11. Bottero JBA, Lemoine M, et al. Current state of and needs for hepatitis B screening: results of a large screening study in a low prevalent, metropolitan region. PLoS One. 2014;9.

  12. Spenatto NBS, Mularczyk M, et al. Hepatitis B screening: who to target? A French sexually transmitted infection clinic experience. J Hepatol. 2013;58:690–7.

    Article  CAS  Google Scholar 

  13. Chou R, Blazina I, Bougatsos C, Holmes R, Selph S, Grusing S, Jou J. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2020;324:2423–36.

    Article  Google Scholar 

  14. Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011-2016. Clin Infect Dis. 2019;69:709–12.

    Article  Google Scholar 

  15. Vijayadeva V, Spradling PR, Moorman AC, Rupp LB, Lu M, Gordon SC, Henkle E, et al. Hepatitis B virus infection testing and prevalence among Asian and Pacific Islanders. Am J Manag Care. 2014;20:e98–e104.

    PubMed  PubMed Central  Google Scholar 

  16. Hu KQ, Pan CQ, Goodwin D. Barriers to screening for hepatitis B virus infection in Asian Americans. Dig Dis Sci. 2011;56:3163–71.

    Article  Google Scholar 

  17. Toy M, Hutton D, Harris AM, Nelson N, Salomon JA, So S. Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States. Clin Infect Dis. 2022;74:210–7.

    Article  Google Scholar 

  18. Sablan BPKD, Barzaga NG, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine. 2012;30:2689–96.

    Article  CAS  Google Scholar 

  19. Hyer RMD, Xing B, Jackson S, Janssen R. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults. Vaccine. 2018;36:2604–11.

    Article  CAS  Google Scholar 

  20. Martha C, Sanchez M. Hepatitis A and B vaccination in the United States, vaccine updates. Rhode Island Medical Journal. 2020.

  21. Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, Nelson NP. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1–31.

    Article  Google Scholar 

  22. Schillie S VC, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep:1-31.

  23. Jilg WSM, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis. 160(5):766–9.

  24. Alonso S, Guerra AR, Carreira L, Ferrer JA, Gutierrez ML, Fernandez-Rodriguez CM. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon? BMC Gastroenterol. 2017;17:168.

    Article  Google Scholar 

  25. Organization WH. Global health sector strategy on viral hepatitis 2016–2021. June 2016.

  26. Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis. 2016;20:607–28.

    Article  Google Scholar 

  27. Rosen HR, Ghany MG, Chung RT, Lok ASF. NAM 2017 report: a national plan to eliminate hepatitis B and C in the United States by 2030 and the AASLD’s response. Hepatology. 2017;66:1020–2.

    Article  Google Scholar 

  28. Group TNHBCSPW. Strategic plan for trans-NIH research to cure hepatitis B. Novmeber. 2019.

  29. Atlanta: US Department of Health and Human Services CfDCaP. Centers for Disease Control and Prevention. Viral hepatitis surveillance—United States, 2017.

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Henry Ford Health System, Detroit, MI, USA

    Omar Shamaa

  2. Department of Gastroenterology and Hepatology, Henry Ford Health System, Detroit, MI, USA

    Vivek Mendiratta & Stuart C. Gordon

  3. Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, USA

    Sheri Trudeau

  4. School of Medicine, Wayne State University, Detroit, MI, USA

    Stuart C. Gordon

  5. Detroit, USA

    Stuart C. Gordon

Authors
  1. Omar Shamaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vivek Mendiratta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sheri Trudeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stuart C. Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Conflict of Interest

Stuart C. Gordon receives grant/research support from AbbVie Pharmaceuticals, Bristol-Myers Squibb, Conatus, CymaBay, Exalenz BioScience, Gilead Pharmaceuticals, Intercept Pharmaceuticals, and Merck.

Other authors have no conflicts of interest to declare.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Hepatitis B

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shamaa, O., Mendiratta, V., Trudeau, S. et al. Evolving Screening and Vaccination Recommendations for Hepatitis B in the USA. Curr Hepatology Rep 21, 37–43 (2022). https://doi.org/10.1007/s11901-022-00583-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-022-00583-3

Keywords

Search

Navigation